02414nas a2200493   4500000000100000008004100001260003700042653002400079653001600103653002400119653001000143653002000153653003900173653001800212100001300230700002100243700001500264700001000279700001400289700001500303700001400318700001400332700001100346700001600357700001300373700001700386700001900403700001400422700001300436700001400449700001500463700001300478700001300491700002000504700002200524700001600546700001500562245010600577856009900683300000900782490000700791520110800798022001401906       2024                            d  bPublic Library of Science (PLoS)10aChromoblastomycosis10aAntifungais10aDiagnostic medicine10aFungi10afungal diseases10aNeglected tropical diseases (NTDs)10aGlobal health1 aSmith DJ1 aQueiroz-Telles F1 aRabenja FR1 aHay R1 aBonifaz A1 aGrijsen ML1 aBlaizot R1 aMessina F1 aSong Y1 aLockhart SR1 aJordan A1 aCavanaugh AM1 aLitvintseva AP1 aChiller T1 aSchito M1 ade Hoog S1 aVicente VA1 aCornet M1 aDagne DA1 aRamarozatovo LS1 ade Azevedo CDMPES1 aSantos DWCL1 aBongomin F00aA global chromoblastomycosis strategy and development of the global chromoblastomycosis working group  uhttps://journals.plos.org/plosntds/article/file?id=10.1371/journal.pntd.0012562&type=printable  a1-120 v183 a<jats:p>Chromoblastomycosis, an implantation mycosis, is a neglected tropical disease that causes decreased quality of life, stigma, and disability. The global burden of disease is unknown and data on disease epidemiology and outcomes are severely limited by a lack of access to needed diagnostic tools and therapeutics. The World Health Organization outlined targets for chromoblastomycosis in the Road Map for Neglected Tropical Diseases 2021–2030, but little progress has been made in initiating and implementing an effective control program globally. This lack of guiding policy and progress led to the recent formation of a Global Chromoblastomycosis Working Group which has developed a global chromoblastomycosis strategy. We describe this strategy, which outlines specific steps needed to improve technical progress, strategy and service delivery, and enablers. Clinicians, researchers, public and government officials, patients, and policy makers can align their time, expertise, and resources to improve the lives of communities affected by chromoblastomycosis through this strategy.</jats:p>  a1935-2735